SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : VICL (Vical Labs)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: F. Jay Abella, III who wrote (450)12/6/1997 4:11:00 PM
From: Brian Malloy  Read Replies (1) of 1972
 
The specific article that I referred to was:

Toward clinical trials of DNA vaccines against malaria
Immunology and Cell Biology (1997) 75, 376-381

In the list of contributors to the article (of which there are 12 total) Peter Hobart and Jon A. Norman of Vical Incorporated, San Diego, California, USA are listed.

While one does not want to overestimate the importance of scientific achievement, it is my opinion that the body of work done by the primary researchers (which probably would not include VICAL at this juncture) with regard to DNA plasmid vaccines and finding weaknesses in the Malaria life cycle that can be exploited by various methods is the type of work that can lead to a Nobel Prize in the future - should they be successful.

The article ends with the following sentence. "DNA vaccines may or may not prove to be the final answer, but they have given us a handle on solving this problem that was previously unavailable."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News